Just an update:
The Swedish Medical Products Agency (called "Läkemedelsverket" in Swedish) updated the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC) for Propecia on 2010-03-18. The old link to the PIL posted in this thread earlier therefore no longer works. The new version of these documents can be found here:
Propecia PIL in English: http://www.lakemedelsverket.se/SPC_PIL/Pdf/enhumpil/Propecia%20film-coated%20tablet%20ENG.doc
Propecia SPC in English: http://www.lakemedelsverket.se/SPC_PIL/Pdf/enhumspc/Propecia%20film-coated%20tablet%20ENG.doc
The SPC for the UK has also been updated with the same info on 2010-04-28, as can be seen on the UK Electronic Medicines Compendium (eMC): http://www.medicines.org.uk/EMC/medicine/3680/SPC/Propecia+1mg+tablets/
. On the eMC website there's also a version history of the document so that it's possible so see what changes occured when: http://www.medicines.org.uk/EMC/history/3680/SPC/Propecia+1mg+tablets
. As far as I can see, the most important addition to what already has been mentioned earlier in this thread is:
* Section 4.4: "[Male] Breast cancer has been reported in men taking finasteride 1 mg during the post-marketing period."
Then the SPC also mentions the following, which already is known but worth emphasizing once again:
* Section 4.4: "Long-term data on fertility in humans are lacking, and specific studies in sub fertile men have not been conducted. [...] spontaneous reports of infertility and /or poor seminal quality were received post-marketing. Normalisation or improvement of seminal quality has been reported after discontinuation of finasteride." (i.e. after discontinuation some only noticed an improvement and not necessarily normalization => possibly persistent infertility).
* Section 4.8: "In addition, the following have been reported in post-marketing use: persistence of erectile dysfunction after discontinuation of treatment with ‘Propecia’; [...]"